Tag Directory / PHARMACEUTICALS     showing 1–8 of 8

for: Saturday, February 14, 2026



Lilly appeals retatrutide classification ruling in case that could impact compounders / Endpoints

Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...

#obesity #healthcare #pharmaceuticals #elililly #weightloss #publichealth #drugdevelopment #fda #digitalhealth

Eli Lilly tests GLP-1 psoriasis combo in phase 3 trial

18 days / beckershospitalreview / Ella Jeffries

Video: Using combined therapy to treat obesity

19 days / medicalxpress

What's next for GLP-1s?

19 days / medicalxpress

Weight-loss drug 'support supplements': Do they address nutrient deficiencies, or are they just another fad?

21 days / medicalxpress

Weight-loss wonder pills prompt scrutiny of their key ingredient

21 days / medicalxpress

Taking the next shot: GLP-1 research and the new era of weight loss

21 days / medicalxpress

Overweight, obesity remained highly prevalent in US youths in 2024

22 days / medicalxpress

Inside Health

22 days / bbc

Bariatric surgery programs face upheaval amid growing GLP-1 use for weight loss

22 days / medicalxpress

Drugs Behind Ozempic and Wegovy Are Being Repurposed — Here Are 5 Others

23 days / discovermagazine

Will Ozempic-style patches help you lose weight? Two experts explain

24 days / medicalxpress

Obesity rates are rising, despite GLP-1s. What does it mean?

24 days / medicalxpress

White-label telehealth provider, pharmacy sued over 'snake oil' compounded oral GLP-1

25 days / fiercehealthcare

Lilly appeals retatrutide classification ruling in case that could impact compounders

25 days / endpoints / Alexis Kramer

Lilly stockpiles $1.5B worth of weight loss pill ahead of US approval

26 days / endpoints / Anna Brown

Saturday, February 14, 2026, 12:21 pm / permalink 19191 / 15 stories in 24 days


HPV cancer vaccine slows tumor growth and extends survival in preclinical model / Medical Express

medicalxpress - Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure. After proving this concept across multiple studies, the…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

This reengineered HPV vaccine trains T cells to hunt down cancer

21 days / sciencedaily

Cancer virus imaging helps uncover potential therapeutic targets

22 days / medicalxpress

Dual brakes on T-cells: New targets found to boost immunity in chronic infections

23 days / medicalxpress

Cancer vaccine shows promise against HPV-related throat tumors in early study

27 days / livescience

HPV cancer vaccine slows tumor growth and extends survival in preclinical model

27 days / medicalxpress

Saturday, February 14, 2026, 5:21 am / permalink 19182 / 5 stories in 25 days


Studies test whether gene-editing can fix high cholesterol. For now, take your medicine / Medical Express

medicalxpress - Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix for high cholesterol.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Nanoparticle-based gene editing could expand treatment options for cystic fibrosis

21 days / medicalxpress

Massive study finds most statin side effects aren’t caused by the drugs

24 days / sciencedaily

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

27 days / go

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

27 days / medicalxpress

Saturday, February 14, 2026, 3:21 am / permalink 19179 / 4 stories in 25 days


Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity

Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …

#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Al-Ola Abdallah: Discussing Updates of CAR-T in Malignant Hematology with Nausheen Ahmed

20 days / oncodaily

J&J pours $1B into new cell therapy site in Pennsylvania

20 days / endpoints / Nicole DeFeudis

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

21 days / endpoints / Elizabeth Cairns

One stem cell generates 14 million tumor-killing NK cells in major cancer breakthrough

21 days / sciencedaily

Caroline Pothet: The 2026 Workplan of the Committee For Advanced Therapies is Available

22 days / oncodaily

Eddie Cliff: Why CAR T Infusion Timing Doesn’t Change Outcomes in LBCL

22 days / oncodaily

Optimizing CAR T-cell therapy to tackle solid tumors

22 days / medicalxpress

Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B

29 days / medcitynews / Frank Vinluan

Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition

4 wks / endpoints / Kyle LaHucik

Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 25 days


Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO / Endpoints

Reynald Castañeda / endpoints - Paul Hudson is stepping down from his post as CEO of Sanofi, and his last day will be Feb. 17. The French drugmaker's board decided not to renew Hudson's mandate on ...

#healthcare #pharmaceuticals #biotech #drugdevelopment

Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more

25 days / endpoints / Nicole DeFeudis

Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO

27 days / endpoints / Reynald Castañeda

Medical neglect contributed to mother's death, inquest finds

27 days / bbc

Saturday, February 14, 2026, 3:20 am / permalink 19177 / 3 stories in 25 days


Ama launches independent vaccine review after CDC criticism / Medical Express

medicalxpress - Two major medical groups will begin reviewing vaccine safety and effectiveness after major changes at the U.S. Centers for Disease Control and Prevention (CDC) have raised alarms among experts.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #cdc #vaccinesafety

Vaccine denial sets Americans up for more chronic illness

24 days / livescience

Large study finds no link between mRNA COVID vaccine in pregnancy and autism

24 days / sciencedaily

Ama launches independent vaccine review after CDC criticism

27 days / medicalxpress

AMA partners with research group to review vaccine safety, effectiveness

29 days / beckershospitalreview / Mackenzie Bean

Saturday, February 14, 2026, 12:22 am / permalink 19173 / 4 stories in 25 days


BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing / MedCity

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing

26 days / medcitynews / Frank Vinluan

BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins

27 days / endpoints / Max Gelman

Saturday, February 14, 2026, 12:22 am / permalink 19171 / 2 stories in 25 days


AbbVie sues over selection of Botox for IRA negotiations / Endpoints

Nicole DeFeudis / endpoints - AbbVie is suing CMS for picking Botox for the third round of Medicare negotiations, making it the first drugmaker to challenge the upcoming cycle in court. In a lawsuit filed Wednesday in Washington, DC, AbbVie ...

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy

AbbVie sues over selection of Botox for IRA negotiations

26 days / endpoints / Nicole DeFeudis

AbbVie sues HHS over Medicare drug price controls

27 days / beckershospitalreview / Ella Jeffries

Saturday, February 14, 2026, 12:22 am / permalink 19169 / 2 stories in 25 days


Back to Top


PHARMACEUTICALS Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.